$8.97
4.78% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US00211Y4070
Symbol
ORKA
Sector
Industry

ARCA biopharma, Inc. Stock price

$9.42
-0.49 4.94% 1M
-15.58 62.32% 6M
-9.97 51.42% YTD
-1.62 14.64% 1Y
-5.68 37.62% 3Y
-8.78 48.24% 5Y
-673.66 98.62% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.14 1.46%
ISIN
US00211Y4070
Symbol
ORKA
Sector
Industry

Key metrics

Market capitalization $352.69m
Enterprise Value $-19.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.33
P/B ratio (TTM) P/B ratio 0.93
Dividend yield 0.00%
Last dividend (FY24) $19.36
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-65.00m
Free Cash Flow (TTM) Free Cash Flow $-58.03m
Cash position $375.65m
EPS (TTM) EPS $-6.43
P/E forward negative
Short interest 48.08%
Show more

Is ARCA biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

ARCA biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a ARCA biopharma, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a ARCA biopharma, Inc. forecast:

Buy
100%

Financial data from ARCA biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
55% 55%
-
- -
-
-
- Selling and Administrative Expenses 13 13
122% 122%
-
- Research and Development Expense 51 51
4,998% 4,998%
-
-65 -65
804% 804%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -65 -65
791% 791%
-
Net Profit -59 -59
1,007% 1,007%
-

In millions USD.

Don't miss a Thing! We will send you all news about ARCA biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ARCA biopharma, Inc. Stock News

Neutral
GlobeNewsWire
27 days ago
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year
Neutral
GlobeNewsWire
28 days ago
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, preclinical data to be presented at the 2025 AAD Annual Meeting; Phase 1 initiation expected in Q...

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Head office United States
CEO Lawrence Klein
Employees 28
Founded 1992
Website www.orukatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today